Given the role of ARID1A in chromatin remodeling, drugs that target epigenetic regulators, such as histone deacetylase (HDAC) inhibitors or DNA methyltransferase inhibitors, may offer therapeutic benefits to patients with ARID1A-mutant cancers [7]. Here, HDAC9 is linked to cancer.